Navigation Links
Synaptics Reports Record Results for First Quarter of Fiscal 2009
Date:10/23/2008

$0.39 $0.27

Shares used in computing net income

per share:

Basic 33,640 39,315

Diluted 35,459 41,537

(1) Includes share-based compensation

charges of:

Cost of revenue $411 $239

Research and development 2,016 1,171

Selling, general, and

administrative 3,454 1,919

$5,881 $3,329

(2) Includes tax benefit for share-

based compensation charges of:

$1,968 $1,697

Non-GAAP net income per share:

Basic $0.53 $0.38

Diluted $0.50 $0.36

Note:

All share and per share amounts reflect the 3-for-2 stock split effected

as a stock dividend and paid on August 29, 2008.

SYNAPTICS INCORPORATED

Computation of Basic and Diluted Net Income Per Share

(in thousands, except per share data)

(Unaudited)

Three Months Ended

September 30,

2008 2007

Numerator:

Basic and diluted net income $13,959 $11,262

Denominator:

Shares, basic 33,640 39,315

Effect of dilutive share-based

awards 1,819 2,222

Shares, diluted
'/>"/>

SOURCE Synaptics Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Synaptics to Report First Quarter Results on October 23
2. Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree
3. GEN reports on novel tools for deciphering biological networks
4. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
5. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
6. Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results
7. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
8. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
9. Limiting fructose may boost weight loss, UT Southwestern researcher reports
10. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
11. BIO-key(R) Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4Scientists discover gene module underlying atherosclerosis development 2Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 1Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 2Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 3Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 4Industry Recognized and Trusted Leader Bruce Matter Joins Healthcare IT Company Peminic Inc as Company Growth in the Areas of Patient Safety Ris 48289 1Industry Recognized and Trusted Leader Bruce Matter Joins Healthcare IT Company Peminic Inc as Company Growth in the Areas of Patient Safety Ris 48289 2BayCare Health System Sleep Disorder Centers Offer Help for Sleepless Nights 48286 1BayCare Health System Sleep Disorder Centers Offer Help for Sleepless Nights 48286 2BayCare Health System Sleep Disorder Centers Offer Help for Sleepless Nights 48286 3
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3